Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection

Hepatology

Volumn 58, Issue 3, 2013, Pages 881-889

  Ashraf, Shirin ^a   Nitschke, Katja ^b   Warshow, Usama M ^c   Brooks, Collin R ^a   Kim, Arthur Y ^d   Lauer, Georg M ^e   Hydes, Theresa J ^a   Cramp, Matthew E ^c   Alexander, Graeme ^f   Little, Ann Margaret ^g   Thimme, Robert ^h   Neumann Haefelin, Christoph ^h   Khakoo, Salim I ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

^c DERRIFORD HOSPITAL   (United Kingdom)

^d Division of Infectious Diseases Laboratory   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f Department of Medicine ^*  (United Kingdom)

^g Laboratory of Histocompatibility and Immunogenetics   (United Kingdom)

^h UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CD8 ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; TAPASIN;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EXON; FEMALE; GENOTYPE; HEPATITIS C; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HLA ANTIGENS; HLA-B ANTIGENS; HUMANS; LOGISTIC MODELS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; TREATMENT OUTCOME;

EID: 84883223002     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26415     Document Type: Article

References (40)

1. Seich Al Basatena NK, Macnamara A, Vine AM, Thio CL, Astemborski J, Usuku K, et al. KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection. PLoS Pathog 2011;7:e1002270.
2. Neumann-Haefelin C, Timm J, Schmidt J, Kersting N, Fitzmaurice K, Oniangue-Ndza C, et al. Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope. Hepatology 2010;51:54-62.
3. Kuniholm MH, Kovacs A, Gao X, Xue X, Marti D, Thio CL, et al. Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology 2010;51:1514-1522.
4. Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007;13:1770-1787.
5. McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004;40:108-114.
6. Fanning LJ, Kenny-Walsh E, Shanahan F. Persistence of hepatitis C virus in a white population: associations with human leukocyte antigen class 1. Hum Immunol 2004;65:745-751.
7. Thio CL, Gao X, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002;76:4792-4797.
8. Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 2011;140:686-696 e681.
9. Bangia N, Cresswell P. Stoichiometric tapasin interactions in the catalysis of major histocompatibility complex class I molecule assembly. Immunology 2005;114:346-353.
10. Lehner PJ, Surman MJ, Cresswell P. Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line.220. Immunity 1998;8:221-231.
11. Williams AP, Peh CA, Purcell AW, McCluskey J, Elliott T. Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity 2002;16:509-520.
12. Dalchau N, Phillips A, Goldstein LD, Howarth M, Cardelli L, Emmott S, et al. A peptide filtering relation quantifies MHC class I peptide optimization. PLoS Comput Biol 2011;7:e1002144.
13. Howarth M, Williams A, Tolstrup AB, Elliott T. Tapasin enhances MHC class I peptide presentation according to peptide half-life. Proc Natl Acad Sci U S A 2004;101:11737-11742.
14. Thirdborough SM, Roddick JS, Radcliffe JN, Howarth M, Stevenson FK, Elliott T. Tapasin shapes immunodominance hierarchies according to the kinetic stability of peptide-MHC class I complexes. Eur J Immunol 2008;38:364-369.
15. Peh CA, Burrows SR, Barnden M, Khanna R, Cresswell P, Moss DJ, et al. HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity 1998;8:531-542.
16. Park B, Lee S, Kim E, Ahn K. A single polymorphic residue within the peptide-binding cleft of MHC class I molecules determines spectrum of tapasin dependence. J Immunol 2003;170:961-968.
17. Belicha-Villanueva A, McEvoy S, Cycon K, Ferrone S, Gollnick SO, Bangia N. Differential contribution of TAP and tapasin to HLA class I antigen expression. Immunology 2008;124:112-120.
18. Thammavongsa V, Raghuraman G, Filzen TM, Collins KL, Raghavan M. HLA-B44 polymorphisms at position 116 of the heavy chain influence TAP complex binding via an effect on peptide occupancy. J Immunol 2006;177:3150-3161.
19. Turnquist HR, Thomas HJ, Prilliman KR, Lutz CT, Hildebrand WH, Solheim JC. HLA-B polymorphism affects interactions with multiple endoplasmic reticulum proteins. Eur J Immunol 2000;30:3021-3028.
20. Ahmad T, Neville M, Marshall SE, Armuzzi A, Mulcahy-Hawes K, Crawshaw J, et al. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum Mol Genet 2003;12:647-656.
21. Williams AP, Bevan S, Bunce M, Houlston R, Welsh KI, Elliott T. Identification of novel Tapasin polymorphisms and linkage disequilibrium to MHC class I alleles. Immunogenetics 2000;52:9-11.
22. Furukawa H, Kashiwase K, Yabe T, Ishikawa Y, Akaza T, Tadokoro K, et al. Polymorphism of TAPASIN and its linkage disequilibria with HLA class II genes in the Japanese population. Tissue Antigens 1998;52:279-281.
23. Bukulmez H, Fife M, Tsoras M, Thompson SD, Twine NA, Woo P, et al. Tapasin gene polymorphism in systemic onset juvenile rheumatoid arthritis: a family-based case-control study. Arthritis Res Ther 2005;7:R285-290.
24. Deshpande A, Wheeler CM, Hunt WC, Peyton CL, White PS, Valdez YE, et al. Variation in HLA class I antigen-processing genes and susceptibility to human papillomavirus type 16-associated cervical cancer. J Infect Dis 2008;197:371-381.
25. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004;305:872-874.
26. Knapp S, Warshow U, Ho KM, Hegazy D, Little AM, Fowell A, et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology 2011;141:320-325, 325 e321-322.
27. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-1406.
28. Dunn PP, Cox ST, Little AM. Sequencing protocols for detection of HLA class I polymorphism. Methods Mol Biol 2003;210:191-222.
29. Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 2006;43:563-572.
30. Williams A, Peh CA, Elliott T. The cell biology of MHC class I antigen presentation. Tissue Antigens 2002;59:3-17.
31. Warshow UM, Riva A, Hegazy D, Thurairajah PH, Kaminski ER, Chokshi S, et al. Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection. J Viral Hepat 2012;19:501-508.
32. Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, et al. Hepatitis C virus (HCV)-specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis 2008;198:1749-1755.
33. Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005;42:104-112.
34. Boulanger DS, Oliveira R, Ayers L, Prior SH, James E, Williams AP, et al. Absence of tapasin alters immunodominance against a lymphocytic choriomeningitis virus polytope. J Immunol 2010;184:73-83.
35. Dong G, Wearsch PA, Peaper DR, Cresswell P, Reinisch KM. Insights into MHC class I peptide loading from the structure of the tapasin-ERp57 thiol oxidoreductase heterodimer. Immunity 2009;30:21-32.
36. Delwart E, Slikas E, Stramer SL, Kamel H, Kessler D, Krysztof D, et al. Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis 2012;205:875-885.
37. Brant LJ, Ramsay ME, Tweed E, Hale A, Hurrelle M, Klapper P, et al. Planning for the healthcare burden of hepatitis C infection: Hepatitis C genotypes identified in England, 2002-2007. J Clin Virol 2010;48:115-119.
38. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
39. Badrinath S, Saunders P, Huyton T, Aufderbeck S, Hiller O, Blasczyk R, et al. Position 156 influences the peptide repertoire and tapasin dependency of human leukocyte antigen B*44 allotypes. Haematologica 2012;97:98-106.
40. Subramaniam NS, Morgan EF, Lee CY, Wetherall JD, Groth DM. Polymorphism of sheep MHC Class IIb gene TAPASIN. Vet Immunol Immunopathol 2010;137:176-180.